Patients with CLL with SPEN mutations had significantly shorter time-to-first treatment compared with patients with wild type SPEN CLL (2.5 vs. 4.07 years, p = 0.01) (Figure 3). The gene discussed is SPEN; the disease is B-cell chronic lymphocytic leukemia.